## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mall Commissioner for Patents P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax. (571)-273-2855

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEB and FUBILIZATION EEE (if required), Blocks 1 through 5 should be completed where appropriate, All further correspondence including the Plants, between extent and motion and results (if required), blocks 1 through 5 should be completed address as appropriate, address as indicated addresses in field (in the plants of the pla

Note: A certificate of mailing can only be used for domestic mailings of the Foc(a) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any charge of address) 02/02/2007 I hereby certify that this Fe(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop 18SUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. 44992 7590 ASTRAZENECA R&D BOSTON 35 GATEHOUSE DRIVE WALTHAM, MA 02451-1215 elizaria i (Signalu m ATTORNEY DOCKET NO. CONFIRMATION NO FILING DATE FIRST NAMED INVENTOR APPLICATION NO. Z70598-IP US 6741 Andrew Austen Mortlock 03/21/2002 10/088.856 TITLE OF INVENTION: THERAPEUTIC QUINAZOLINE DERIVATIVES PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE DATE DUE ISSUE FEE DUE APPLN, TYPE SMALL ENTITY \$1400 05/07/2007 NO \$1400 cn nonprovisional CLASS-SUBCLASS ART UNIT EXAMINER 514-266200 COLEMAN, BRENDA LIBBY 1624 Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, Change of correspondence address (or Change of Corresponde Address form PTO/SB/122) attached. (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Custon Number is required. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filling an assignment. (B) RESIDENCE: (CTTY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE SE-15185 Södertälje AstraZeneca AB Sweden ☐ Individual ☐ Corporation or other private group entity ☐ Government Please check the appropriate assignee category or categories (will not be printed on the patent): 4b. Payment of Fee(s); (Please first reapply any previously paid issue fee shown above) 4s. The following fec(s) are submitted: Issue Fee A check is enclosed. Payment by credit card. Form PTO-2038 is attached. Publication Fee (No small entity discount permitted) Advance Order - # of Copies 2 The Director is hereby authorized to charge the required fec(s), any deficiency, or credit any overpayment, to Deposit Account Number 50 = 3231 (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyons other than the applicant; a registered attorney or agent; or the assignce or other party in interest as shown by the records of the United States Fatert and Indomnt's Office. Date May 4, 2007 Authorized Signature / Lucy Padget/ Typed or printed name Lucy Padget Registration No. \_ LOO74 This collection of information is required by 37 CFR 1311, the information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Consideration is a process to a process of the proce Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number